Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IGM Biosciences Inc IGMS

Healthcare Biotechnology
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites.... see more

Recent & Breaking News (NDAQ:IGMS)

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2024

IGM Biosciences to Present at Three Upcoming Investor Conferences

GlobeNewswire November 4, 2024

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

GlobeNewswire September 30, 2024

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

GlobeNewswire September 10, 2024

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2024

IGM Biosciences to Present at the Jefferies Healthcare Conference

GlobeNewswire May 29, 2024

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 8, 2024

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference

GlobeNewswire May 7, 2024

IGM Biosciences Announces Refocusing of Sanofi Collaboration

GlobeNewswire April 17, 2024

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

GlobeNewswire April 10, 2024

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 7, 2024

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire February 1, 2024

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

GlobeNewswire December 5, 2023

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

PR Newswire December 1, 2023

Medivir to present at the Erik Penser Bank Company Event

PR Newswire November 21, 2023

IGM Biosciences Announces Third Quarter 2023 Financial Results

GlobeNewswire November 13, 2023

IGM Biosciences to Present at Two Upcoming Investor Conferences

GlobeNewswire November 7, 2023

Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles

PR Newswire October 5, 2023

IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors

GlobeNewswire October 3, 2023